Related Experiment Video
Updated: May 29, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Hydroxyurea Therapy and Sleep-Disordered Breathing in Children With Sickle Cell Disease
Zachary Abramson1, Ayobami Olanrewaju2,3, Guolian Kang4
1Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Hydroxyurea therapy may improve sleep-disordered breathing in sickle cell disease patients by reducing inflammation. Further research is needed to confirm these findings and understand the complex relationship between these conditions.
Area of Science:
- Hematology
- Pulmonology
- Pharmacology
Background:
- Sickle cell disease (SCD) is linked to sleep-disordered breathing (SDB).
- Hydroxyurea is a common treatment for SCD, but its effects on SDB are not fully understood.
- The interplay between SCD, SDB, and hydroxyurea therapy is complex and requires further investigation.
Purpose of the Study:
- To simultaneously investigate the relationships among SCD, SDB, and hydroxyurea therapy.
- To identify correlations and suggest potential pathophysiological mechanisms.
- To explore the impact of hydroxyurea on SDB and inflammation in SCD patients.
Main Methods:
- Cross-sectional study design examining SCD patients.
- Assessment of sleep-disordered breathing (SDB) parameters.
- Measurement of inflammatory markers.
- Analysis of hydroxyurea therapy status.
Main Results:
- Hydroxyurea therapy was associated with improved SDB.
- Hydroxyurea therapy correlated with decreased inflammation.
- Anti-inflammatory effects of hydroxyurea are implicated as a potential mechanism.
Conclusions:
- Hydroxyurea therapy may positively impact SDB in SCD patients.
- Reduced inflammation appears to be a key mechanism linking hydroxyurea to improved SDB.
- Longitudinal studies are essential to establish causality.
More Related Videos
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:54Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...